Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis - PharmaTimes MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups

#PharmaTimes #pharma #pharmaceuticals #Brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #MHRA #MedicinesandHealthcareproductsRegulatoryAgency #marketingauthorisation #chroniccondition #dipeptidylpeptidase1 #inflammatoryprocess #lungs #respiratory #JulianBeach
zurl.co/LPYPc

Insmed's 2025 Financial Results Show Robust Growth and Future Prospects for BRINSUPRI Insmed has reported strong financial results for 2025, highlighting significant growth in revenues from BRINSUPRI and ARIKAYCE. The company anticipates continued expansion in 2026.

Insmed's 2025 Financial Results Show Robust Growth and Future Prospects for BRINSUPRI #United_States #Bridgewater #Insmed #ARIKAYCE #Brinsupri

Medicare still denying the medication that my mom's pulmonologist perscribed to ... help her breathe. #brinsupri is the only medication that can treat her condition, but #medicare and #humana would rather she die. Maybe #Insmed can help.

Insmed Releases Business Update and Future Outlook at J.P. Morgan Healthcare Conference Insmed presented significant revenue growth and future plans for their drug portfolio during the J.P. Morgan Healthcare Conference.

Insmed Releases Business Update and Future Outlook at J.P. Morgan Healthcare Conference #United_States #San_Francisco #Insmed #ARIKAYCE #Brinsupri

New season of #NTM talk podcast series. I just listened to the latest episode about our new #bronchiectasis drug, #BRINSUPRI and exacerbations. For topics & links go to my website blog:

www.letsbecleartoday.com/be-clear-blo...

European Commission Gives Green Light to BRINSUPRI® as Breakthrough Therapy for Non-Cystic Fibrosis Bronchiectasis The European Commission has officially approved BRINSUPRI® (brensocatib) as the groundbreaking treatment for non-cystic fibrosis bronchiectasis, a first of its kind in the EU.

European Commission Gives Green Light to BRINSUPRI® as Breakthrough Therapy for Non-Cystic Fibrosis Bronchiectasis #None #Insmed #Bronchiectasis #Brinsupri

European Commission Approves BRINSUPRI™ as First Treatment for Non-Cystic Fibrosis Bronchiectasis The European Commission has officially authorized BRINSUPRI™ (brensocatib) as the sole treatment for non-cystic fibrosis bronchiectasis, marking a crucial advancement in patient care.

European Commission Approves BRINSUPRI™ as First Treatment for Non-Cystic Fibrosis Bronchiectasis #None #Bronchiectasis #Brinsupri #Non-Cystic_Fibrosis

Insmed Reports Impressive Third-Quarter 2025 Financial Results and Updates on Product Launches Insmed Incorporated shares its third-quarter 2025 financial results, highlighting significant progress in treatment approvals and revenue growth for its products.

Insmed Reports Impressive Third-Quarter 2025 Financial Results and Updates on Product Launches #United_States #Insmed #ARIKAYCE #Bridgewater,_NJ #Brinsupri

CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, and other CHMP decisions.

#bronchiectasis #respiratory #CHMP #Insmed #brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #NCFB #ASPENtrial #Sanofi #Wayrilz #rilzabrutinib #immunethrombocytopenia #ITP #SanofiWinthrop #Rezurock #belumosudil #chronicgraftversushostdisease #GvHD #transplant #KadmonPharma
zurl.co/r27x2

Insmed to Showcase Pioneering Phase 3 ASPEN Study Results at CHEST 2025 Insmed reveals key findings from the Phase 3 ASPEN trial on BRINSUPRI™ at CHEST 2025, focusing on efficacy for non-CF bronchiectasis.

Insmed to Showcase Pioneering Phase 3 ASPEN Study Results at CHEST 2025 #United_States #Chicago #Insmed #Brinsupri #CHEST_2025

Couldn’t sleep last night processing all the fantastic news for our #bronchiectasis & #NTM community. Thank you Dr Daley & the NJH team for a fabulous patient conference‼️ #BRINSUPRI #brensocatib #AirwayClearance #CareCenters

VytlOne and Insmed Collaborate for Brinsupri Distribution in NCFB Treatment VytlOne announces a partnership with Insmed, becoming a limited distributor for Brinsupri™, the first FDA-approved drug for bronchiectasis.

VytlOne and Insmed Collaborate for Brinsupri Distribution in NCFB Treatment #USA #Amarillo #Insmed #VytlOne #Brinsupri